Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and
Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women
CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG
has finished recruitment for a multi-center Phase III study exploring the
safety and efficacy of Salmon Calcitonin and Emisphere's proprietary
Eligen(R) Technology in the treatment of vertebral fractures in
postmenopausal women aged 60-80 with osteoporosis. The last of 4,500+
patients was recruited in the final week of June, and the three-year study
will be conducted in North and South America, Europe and Asia.
Osteoporosis is a disease associated with a gradual thinning and
weakening of the bones, occurring most frequently in women after menopause.
Thinner and weaker bones are increasingly susceptible to fractures.
Untreated postmenopausal osteoporosis can lead to chronic back pain,
disabling fractures, and lost mobility.
"This Phase III study provides yet another application of our Eligen(R)
Technology in the fight against osteoporosis. Safe, effective and rapid
treatment will make a difference in the lives of millions of American women
who are afflicted with the disease," said Michael V. Novinski, President
and Chief Executive Officer of Emisphere.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules using
its Eligen(R) Technology. These molecules and compounds could be currently
available or in development. Such molecules are usually delivered by
injection; in many cases, their benefits are limited due to poor
bioavailability, slow on-set of action or variable absorption. The
Eligen(R) Technology can be applied to the oral route of administration as
well other delivery pathways, such as buccal, rectal, inhalation,
intra-vaginal or transdermal. The website is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 5, 2007 and our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2007, filed on May 7, 2007.
For further information contact:
Bob Madison, Senior Director Corporate Communications
973-532-8001 or bmadison@emisphere.com
Adam Friedman, Adam Friedman Associates
212-981-2529, extension 18 or adam@adam-friedman.com
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
CONTACT:
Bob Madison, Senior Director Corporate
Communications, +1-973-532-8001, bmadison@emisphere.com; or Adam
Friedman of Adam Friedman Associates, +1-212-981-2529, extension
18, adam@adam-friedman.com
|
